CML patients with BCR::ABL1/b2a3 or BCR::ABL1/b3a3 variants have been excluded from these studies, although post-marketing experience has demonstrated excellent outcomes with orthosteric TKIs [10–12]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.